This programmatic update indicates that Options B and specifically B+ are likely to prove preferable to Option A for operational, programmatic and strategic reasons. While Option A has been successfully implemented in a number of highburden countries, generally it has been difficult to implement in many low-resource settings due to the changes in drugs delivered across the care continuum (antenatal, delivery and postpartum) and the requirement for timely CD4 testing to determine which women shou